Comparative effectiveness of combination first-line therapies for metastatic renal cell carcinoma (mRCC).

被引：1
|
作者：
Shay, Rebecca C.
Nicklawsky, Andrew
Lam, Elaine Tat
机构：
[1] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
[2] Univ Colorado, Canc Ctr, Anschutz Med Campus, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16549
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16549
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
    Ernst, Matthew Scott
    Navani, Vishal
    Wells, J. Connor
    Donskov, Frede
    Basappa, Naveen S.
    Labaki, Chris
    Pal, Sumanta K.
    Meza, Luis A.
    Wood, Lori
    Ernst, D. Scott
    Szabados, Bernadett
    Mckay, Rana R.
    Parnis, Francis
    Suarez, Cristina
    Yuasa, Takeshi
    Kapoor, Anil
    Alva, Ajjai Shivaram
    Bjarnason, Georg A.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] COMPARATIVE EFFECTIVENESS OF FIRST-LINE IMMUNOTHERAPY, TARGETED THERAPY, AND COMBINATION THERAPY FOR METASTATIC CLEAR CELL RENAL CELL CARCINOMA
    Chakiryan, Nicholas
    Jiang, David
    Gillis, Kyle
    Green, Elizabeth
    Hajiran, Ali
    Hugar, Lee
    Zemp, Logan
    Chahoud, Jad
    Zhang, Jingsong
    Jain, Rohit
    Sexton, Wade
    Gilbert, Scott
    Manley, Brandon
    JOURNAL OF UROLOGY, 2021, 206 : E678 - E678
  • [3] Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
    Barragan-Carrillo, Regina
    Chawla, Neal Shiv
    Salgia, Nicholas
    Meza, Luis A.
    Zengin, Zeynep Busra
    Li, Xiaochen
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Hsu, Joann
    Castro, Daniela V.
    Mercier, Benjamin D.
    Dorff, Tanya B.
    Tripathi, Abhishek
    Bergerot, Cristiane Decat
    Bergerot, Paulo Gustavo
    Chehrazi-Raffle, Alex
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS491 - TPS491
  • [4] The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)
    Navani, V.
    Ernst, M. S.
    Takemura, K.
    Pal, S. K.
    Powles, T. B.
    Donskov, F.
    Wells, J. C.
    Kollmannsberger, C. K.
    Beuselinck, B.
    Alva, A. S.
    Weickhardt, A. J.
    Lalani, A-K.
    Ernst, D. S.
    Agarwal, N.
    Choueiri, T. K.
    Heng, D. Y. C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1215 - S1216
  • [5] TOLERABILITY OF TARGETED AGENTS IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Su, Y.
    Shi, N.
    Landsman-Blumberg, P.
    Poehlein, C.
    Waxman, I.
    ANNALS OF ONCOLOGY, 2012, 23 : 267 - 268
  • [6] First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
    Vano, Yann-Alexandre
    Ladoire, Sylvain
    Elaidi, Reza
    Dermeche, Slimane
    Eymard, Jean-Christophe
    Falkowski, Sabrina
    Gross-Goupil, Marine
    Malouf, Gabriel
    Narciso, Berangere
    Sajous, Christophe
    Tartas, Sophie
    Voog, Eric
    Ravaud, Alain
    CANCERS, 2021, 13 (21)
  • [7] Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma
    Ernst, Matthew S.
    Navani, Vishal
    Wells, J. Connor
    Donskov, Frede
    Basappa, Naveen
    Labaki, Chris
    Pal, Sumanta K.
    Meza, Luis
    Wood, Lori A.
    Ernst, D. Scott
    Szabados, Bernadett
    McKay, Rana R.
    Parnis, Francis
    Suarez, Cristina
    Yuasa, Takeshi
    Lalani, Aly-Khan
    Alva, Ajjai
    Bjarnason, Georg A.
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN UROLOGY, 2023, 84 (01) : 109 - 116
  • [8] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN COLOMBIA (ONCOLGROUP STUDY)
    Godoy, J., I
    Cardona, A. F.
    Caceres, H. A.
    Otero, J. M.
    Lujan, M.
    Lopera, D.
    Pacheco, J. O.
    Spath, A.
    Gis, P. R.
    VALUE IN HEALTH, 2009, 12 (07) : A495 - A495
  • [9] Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study)
    Godoy, J.
    Cardona, A. F.
    Caceres, H.
    Otero, J. M.
    Lujan, M.
    Lopera, D.
    Pacheco, J. O.
    Spath, A.
    Gis, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345